irasia.com - Investor Relations Asia Pacific
HOME

CSPC Pharmaceutical Group Limited
(Formerly known as China Pharmaceutical Group Limited)
(Incorporated in Hong Kong under the Companies Ordinance)

Announcements & Notices       


Please download the latest "Acrobat Reader" to view the PDF.

  • 2018-December-11
  • PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE (in PDF)
  • 2018-November-26
  • VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "AMOXICILLIN CAPSULES" (in PDF)
  • 2018-November-26
  • VOLUNTARY ANNOUNCEMENT - THE GROUP'S "TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" WAS GRANTED DRUG REGISTRATION APPROVAL (in PDF)
  • 2018-November-26
  • VOLUNTARY ANNOUNCEMENT - THE GROUP'S PRODUCT CANDIDATE "ALMB-0166" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
  • 2018-November-19
  • UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018 (in PDF)
  • 2018-November-7
  • DATE OF BOARD MEETING (in PDF)
  • 2018-November-1
  • CONTINUING CONNECTED TRANSACTION - RENEWAL OF MASTER SALES AGREEMENT (in PDF)
  • 2018-October-8
  • VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT (in PDF)
  • 2018-September-26
  • VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSE AND COLLABORATION AGREEMENT (in PDF)
  • 2018-August-30
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2018-August-30
  • RESIGNATION OF DIRECTOR (in PDF)
  • 2018-August-20
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2018-August-20
  • APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES (in PDF)
  • 2018-August-20
  • ADOPTION OF RESTRICTED SHARE AWARD SCHEME (in PDF)
  • 2018-August-20
  • 2018 INTERIM RESULTS ANNOUNCEMENT (in PDF)
  • 2018-August-8
  • DATE OF BOARD MEETING (in PDF)
  • 2018-August-6
  • CONNECTED TRANSACTION - ACQUISITION OF 29.9% EQUITY INTEREST IN CSPC YUANDA (DALIAN) PHARMACEUTICAL CO., LTD. (in PDF)
  • 2018-July-23
  • VOLUNTARY ANNOUNCEMENT - "STATE KEY LABORATORY FOR NOVEL PHARMACEUTICAL PREPARATIONS AND EXCIPIENTS" RATED AS EXCELLENT CLASS OF STATE KEY LABORATORY (in PDF)
  • 2018-July-10
  • VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT (in PDF)
  • 2018-July-10
  • VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA (in PDF)
  • 2018-July-10
  • VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CAPTOPRIL TABLETS" (in PDF)
  • 2018-July-9
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2018-July-9
  • APPOINTMENT OF EXECUTIVE DIRECTOR (in PDF)
  • 2018-June-4
  • VOLUNTARY ANNOUNCEMENT - ADMISSION OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" TO THE "LIST OF MARKETED DRUGS OF CHINA" (in PDF)
  • 2018-May-25
  • POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 25 MAY 2018 (in PDF)
  • 2018-May-25
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2018-May-25
  • APPOINTMENT OF VICE-CHAIRMAN AND CHANGE OF ROTATING CHIEF EXECUTIVE OFFICER (in PDF)
  • 2018-May-25
  • UNAUDITED RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2018 (in PDF)
  • 2018-May-21
  • VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "QIMAITE" (TRAMADOL HYDROCHLORIDE TABLETS) (in PDF)
  • 2018-May-14
  • DATE OF BOARD MEETING (in PDF)
  • 2018-May-10
  • VOLUNTARY ANNOUNCEMENT - "Q101-PEGYLATED RECOMBINANT HUMAN INTERFERON-alpha2a FOR INJECTION" FOR THE TREATMENT OF HEPATITIS WAS GRANTED CLINICAL TRIAL APPROVAL (in PDF)
  • 2018-May-10
  • VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "DOXOFYLLINE GLUCOSE FOR INJECTION" AND "DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION" (in PDF)
  • 2018-April-20
  • NOTICE OF ANNUAL GENERAL MEETING (in PDF)
  • 2018-April-18
  • VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AGREEMENT (in PDF)
  • 2018-April-16
  • VOLUNTARY ANNOUNCEMENT - "VINORELBINE TARTRATE LIPOSOME INJECTION" FOR THE TREATMENT OF LUNG CANCER WAS GRANTED CLINICAL TRIAL APPROVAL (in PDF)
  • 2018-April-12
  • VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR"WEIHONG"(AZITHROMYCIN TABLETS) (in PDF)
  • 2018-March-19
  • ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 (in PDF)
  • 2018-March-16
  • VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED DRUG CLINICAL TRIAL APPROVAL (in PDF)
  • 2018-March-11
  • VOLUNTARY ANNOUNCEMENT - THE GROUP'S DRUG "BUTYLPHTHALIDE" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
  • 2018-March-7
  • DATE OF BOARD MEETING (in PDF)
  • 2018-February-12
  • VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" (in PDF)
  • 2018-February-6
  • VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA (in PDF)
  • 2018-January-9
  • VOLUNTARY ANNOUNCEMENT - ACQUISITION OF 39.56% EQUITY INTEREST IN WUHAN YZY BIOPHARMA CO., LTD. (in PDF)
  • 2017
  • 2017 Announcements & Notices
  • 2016
  • 2016 Announcements & Notices
  • 2015
  • 2015 Announcements & Notices
  • 2014
  • 2014 Announcements & Notices
  • 2013
  • 2013 Announcements & Notices
  • 2012
  • 2012 Announcements & Notices
  • 2011
  • 2011 Announcements & Notices
  • 2010
  • 2010 Announcements & Notices
  • 2009
  • 2009 Announcements & Notices
  • 2008
  • 2008 Announcements & Notices
  • 2007
  • 2007 Announcements & Notices
  • 2006
  • 2006 Announcements & Notices


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Disclaimer
    © Copyright 1996-2018 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.